Hematology

Bayer has announced the FDA’s acceptance of its Biologics License Application (BLA) for BAY94-9027 for the treatment of hemophilia A in adults and adolescents aged 12 years or older.

Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.

Results of the Phase 3 ARROW trial revealed that patiehts with refractory multiple myeloma can live up to 3.6 months longer, without their disease worsening, when Kyprolis (carfilzomib) is administered once-weekly at the 70 mg/m2 dose with dexamethasone rather than Kyprolis administered twice-weekly at the 27 mg/m2 dose with dexamethasone, according to Amgen.

Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.

CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.

Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.

The study found that young patients with leukemia who have been vaccinated against the influenza virus are as susceptible to develop flu as their unvaccinated peers.

With the clinical and financial implications of high-cost medications, and their impact on health system revenue, it is of utmost importance for all key stakeholders to be engaged in the complex revenue cycle.

A recent study found that excess body fat in the abdomen and pelvis may predict poor treatment response in patients with multiple myeloma.

Evidence-Based OncologyTM sat down with Brandon R. Shank, PharmD, MPH, BCOP, clinical pharmacy specialist, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, to understand a pharmacist's role in administering chimeric antigen receptor (CAR) T cells.

Following the phase 3 ENDEAVOR trial that compared 2 proteasome inhibitors-carfilzomib and bortezomib-in relapsed or refractory multiple myeloma patients, researchers conducted a second interim analysis to compare the overall survival between the 2 groups.

A recent survey by The Leukemia & Lymphoma Society found that the majority of adults are surprised by the prevalence of blood cancers-specifically the prevalence of acute lymphocytic leukemia among children and young adults.

A recent report, “Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017,” presents a summary of drugs in development to treat chemotherapy-related toxicities.

New results published in CDC’s Morbidity and Mortality Weekly Report have identified a surge in pediatric acute lymphoblastic leukemia (ALL) during the period 2001 to 2008, followed by stabilization during 2008 to 2014.

Patients with relapsed follicular lymphoma now have a new treatment option: copanlisib, a kinase inhibitor that was recently approved through the FDA’s accelerated approval process.

The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.

The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.

A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.

The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Patient reported data can be a reliable source of information to ascertain comorbidities in patients with prostate cancer, says JAMA Oncology study.

The results of a phase 2 study that explored the effects of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) were presented at the 22nd Congress of the European Hematology Association by Acceleron Pharma Inc. The company is developing the drug with Celgene.